AKUH begins clinical preliminary on new disease treatment
AKUH begins clinical preliminary on new disease treatment
The Aga Khan University Hospital, Nairobi (AKUH,N) [1] has launched a first in Africa cancer drug clinical trial to investigate the effectiveness of the newly developed treatment for cancer. This clinical trial follows approval of a similar drug to treat lung cancer by the USA's FDA in 2021 [2].
It is intended to block the uncontrolled cell growth and division of cancer in those patients who are affected by the KRAS gene mutation. The hospital's Clinical Research Unit, headed by the director of the Aga Khan University's Cancer Centre, Mansoor Saleh, is dedicated to spearheading cancer clinical trials and formulating the cornerstone of cancer treatment research [3].
The first patient on the trial is a Ugandan national, and the hospital is hopeful that the new trial will bring positive results for the people affected by this gene mutation.
The Aga Khan College Medical Clinic in Nairobi (AKUH,N) has launched a first-of-its-kind in Africa disease drug clinical preliminary to investigate the viability of a different treatment that impedes the progression of a quality change responsible for the development of malignant growth in affected patients. The primary African location selected for the trial of this novel therapy is AKUH,N.
The evaluation comes after the Food and Drug Administration (FDA) of the United States approved a comparable drug to treat cellular breakdown in the lungs in 2021.
Prof. Mansoor Saleh, the Director of the Aga Khan College's Malignant growth Community and the Clinic's Clinical Exploration Unit (CRU), explains that the quality being discussed is the KRAS quality:

Comments
Post a Comment